Matinas BioPharma Holdings (NYSEAMERICAN:MTNB), a clinical-stage biopharmaceutical company, dedicated to enhancing intracellular delivery of critical therapeutics via its cutting edge lipid nanocrystal (LNC) platform delivery technology, has just nominated Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors. The election is scheduled to take place at the 2021 Annual Meeting of Stockholders on November 1, 2021.
As of now, Ms. Corzo is a partner at Takeda Ventures. Prior to that she worked at Takeda Pharmaceuticals, and headed their Oncology Cell Therapy Development section. Currently, she is situated at Takeda’s R&D hub in Cambridge, Massachusetts. She is thrilled to join the company as she sees excellent potential in the LNC platform to transform the intracellular delivery of complex molecules.
Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors, and Chair of the Nominating and Governance Committee, holds Ms. Corzo in high regard as a biotechnology executive with vast expertise in drug development. He believes her previous record at major pharmaceutical companies will be of immense value in expanding the utilization of the LNC platform delivery technology.
On the other hand, Patrick LePore won’t stand for re-election at the Stockholders Meeting. Jerome D. Jabbour, Chief Executive Officer of Matinas has thanked him for his contribution to the company, and wished him the best for the future.
Market Reaction:
On Friday, MTNB stock jumped 5% at $1.51 with more than 7.01 million shares, compared to its average volume of 1.84 million shares. The stock has moved within a range of $1.3100 – 1.5500 after opening the trade at $1.42.s
